Quantitative Analysis of Vaccine Antigen Adsorption to Aluminum Adjuvant Using an Automated High-Throughput Method

References

1. 1.↵
   1. Kroger A.,
   2. Hamborsky J.,
   3. Wolf C.

   , Eds. Vaccine Excipient & Media Summary. In Epidemiology and Prevention of Vaccine-Preventable Diseases, 13th ed.; Public Health Foundation: Washington, DC, 2015.
2. 2.↵
   1. Vichnin M.,
   2. Bonanni P.,
   3. Klein N. P.,
   4. Garland S. M.,
   5. Block S. L.,
   6. Kjaer S. K.,
   7. Sings H. L.,
   8. Perez G.,
   9. Haupt R. M.,
   10. Saah A. J.,
   11. Lievano F.,
   12. Velicer C.,
   13. Drury R.,
   14. Kuter B. J.

   An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015. The Pediatric Infectious Disease Journal 2015, 34 (9), 983–991.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Glenny A. T.

   Insoluble Precipitates in Diphtheria and Tetanus Immunization. Br. Med. J. 1930, 2 (3632), 244–245.

   OpenUrlFREE Full Text
4. 4.↵
   1. Kool M.,
   2. Soullie T.,
   3. van Nimwegen M.,
   4. Willart M. A.,
   5. Muskens F.,
   6. Jung S.,
   7. Hoogsteden H. C.,
   8. Hammad H.,
   9. Lambrecht B. N.

   Alum Adjuvant Boosts Adaptive Immunity by Inducing Uric Acid and Activating Inflammatory Dendritic Cells. The Journal of Experimental Medicine 2008, 205 (4), 869–882.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Sharp F. A.,
   2. Ruane D.,
   3. Claass B.,
   4. Creagh E.,
   5. Harris J.,
   6. Malyala P.,
   7. Singh M.,
   8. O'Hagan D. T.,
   9. Petrilli V.,
   10. Tschopp J.,
   11. O'Neill L. A.,
   12. Lavelle E. C.

   Uptake of Particulate Vaccine Adjuvants by Dendritic Cells Activates the NALP3 Inflammasome. Proceedings of the National Academy of Sciences of the United States of America 2009, 106 (3), 870–875.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Ghimire T. R.,
   2. Benson R. A.,
   3. Garside P.,
   4. Brewer J. M.

   Alum Increases Antigen Uptake, Reduces Antigen Degradation and Sustains Antigen Presentation by DCs In Vitro. Immunology Letters 2012, 147 (1–2), 55–62.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. McKee A. S.,
   2. Burchill M. A.,
   3. Munks M. W.,
   4. Jin L.,
   5. Kappler J. W.,
   6. Friedman R. S.,
   7. Jacobelli J.,
   8. Marrack P.

   Host DNA Released in Response to Aluminum Adjuvant Enhances MHC Class II-Mediated Antigen Presentation and Prolongs CD4 T-cell Interactions with Dendritic Cells. Proceedings of the National Academy of Sciences of the United States of America 2013, 110 (12), E1122–E1131.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Romero Mendez I. Z.,
   2. Shi Y.,
   3. HogenEsch H.,
   4. Hem S. L.

   Potentiation of the Immune Response to Non-Adsorbed Antigens by Aluminum-Containing Adjuvants. Vaccine 2007, 25 (5), 825–833.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Chang M.,
   2. Shi Y.,
   3. Nail S. L.,
   4. HogenEsch H.,
   5. Adams S. B.,
   6. White J. L.,
   7. Hem S. L.

   Degree of Antigen Adsorption in the Vaccine or Interstitial Fluid and Its Effect on the Antibody Response in Rabbits. Vaccine 2001, 19 (20–22), 2884–2889.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Burdman J.,
    2. Powell M. F.,
    3. Newman M, J,

    1. Gupta R. K.,
    2. Rost B. E.,
    3. Relyveld E.,
    4. Silber G. R.

    Adjuvant Properties of Aluminum and Calcium Compounds In Vaccine Design: The Subunit and Adjuvant Approach, Burdman J., Powell M. F., Newman M, J,; Ed.; Plenum: New York, 1995; p 327.
11. 11.↵
    1. Ruiz W.,
    2. McClements W. L.,
    3. Jansen K. U.,
    4. Esser M. T.

    Kinetics and Isotype Profile of Antibody Responses in Rhesus Macaques Induced Following Vaccination with HPV 6, 11, 16 and 18 L1-Virus-Like Particles Formulated with or without Merck Aluminum Adjuvant. Journal of Immune Based Therapies and Vaccines 2005, 3 (1), 2.

    OpenUrl
12. 12.↵
    1. Caulfield M. J.,
    2. Shi L.,
    3. Wang S.,
    4. Wang B.,
    5. Tobery T. W.,
    6. Mach H.,
    7. Ahl P. L.,
    8. Cannon J. L.,
    9. Cook J. C.,
    10. Heinrichs J. H.,
    11. Sitrin R. D.

    Effect of Alternative Aluminum Adjuvants on the Absorption and Immunogenicity of HPV16 L1 VLPs in Mice. Human Vaccines 2007, 3 (4), 139–145.

    OpenUrl
13. 13.↵
    1. Jones L. S.,
    2. Peek L. J.,
    3. Power J.,
    4. Markham A.,
    5. Yazzie B.,
    6. Middaugh C. R.

    Effects of Adsorption to Aluminum Salt Adjuvants on the Structure and Stability of Model Protein Antigens. The Journal of Biological Chemistry 2005, 280 (14), 13406–13414.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Ripley S.

    Guidance for Industry for the Evaluation of Combination Vaccines for Preventable Diseases: Production, Testing, and Clinical Studies. Research, C. f. B. E. a., Ed. FDA: Rockville, MD, 1997; pp 9–10.
15. 15.↵
    U.S. Food and Drug Administration. Guidance for Industry. Q8 (R2) Pharmaceutical Development. 2009.
16. 16.↵
    1. Jully V.,
    2. Moniotte N.,
    3. Mathot F.,
    4. Lemoine D.,
    5. Preat V.

    Development of a High-Throughput Screening Platform To Study the Adsorption of Antigens onto Aluminum-Containing Adjuvants. J. Pharm. Sci. 2015, 104 (2), 557–565.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Loughney J. W.,
    2. Lancaster C.,
    3. Ha S.,
    4. Rustandi R. R.

    Residual Bovine Serum Albumin (BSA) Quantitation in Vaccines Using Automated Capillary Western Technology. Anal. Biochem. 2014, 461, 49–56.

    OpenUrl
18. 18.↵
    1. Adamson A. W.

    1. Adamson A. W.

    Adsorption of Gases and Vapors on Solids. In Physical Chemistry of Surfaces, Adamson A. W., Ed.; John Wiley & Sons, Inc.: New York, 1982; pp 521–531.
19. 19.↵
    1. Seeber S. J.,
    2. White J. L.,
    3. Hem S. L.

    Predicting the Adsorption of Proteins by Aluminium-Containing Adjuvants. Vaccine 1991, 9 (3), 201–203.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Latour R. A.

    The Langmuir Isotherm: A Commonly Applied but Misleading Approach for the Analysis of Protein Adsorption Behavior. Journal of Biomedical Materials Research, Part A 2015, 103 (3), 949–958.

    OpenUrlPubMed
21. 21.↵
    1. Hansen B.,
    2. Belfast M.,
    3. Soung G.,
    4. Song L.,
    5. Egan P. M.,
    6. Capen R.,
    7. Hogenesch H.,
    8. Mancinelli R.,
    9. Hem S. L.

    Effect of the Strength of Adsorption of Hepatitis B Surface Antigen to Aluminum Hydroxide Adjuvant on the Immune Response. Vaccine 2009, 27 (6), 888–892.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Egan P. M.,
    2. Belfast M. T.,
    3. Gimenez J. A.,
    4. Sitrin R. D.,
    5. Mancinelli R. J.

    Relationship between Tightness of Binding and Immunogenicity in an Aluminum-Containing Adjuvant-Adsorbed Hepatitis B Vaccine. Vaccine 2009, 27 (24), 3175–3180.

    OpenUrlPubMed
23. 23.↵
    1. Wang S. L.,
    2. Johnston C. T.,
    3. Bish D. L.,
    4. White J. L.,
    5. Hem S. L.

    Water-Vapor Adsorption and Surface Area Measurement of Poorly Crystalline Boehmite. Journal of Colloid and Interface Science 2003, 260 (1), 26–35.

    OpenUrlCrossRefPubMedWeb of Science
24. 24.↵
    1. Burrell L. S.,
    2. Johnston C. T.,
    3. Schulze D.,
    4. Klein J.,
    5. White J. L.,
    6. Hem S. L.

    Aluminium Phosphate Adjuvants Prepared by Precipitation at Constant pH. Part I: Composition and Structure. Vaccine 2000, 19 (2–3), 275–281.

    OpenUrlPubMed
25. 25.↵
    1. Burrell L. S.,
    2. Johnston C. T.,
    3. Schulze D.,
    4. Klein J.,
    5. White J. L.,
    6. Hem S. L.

    Aluminium Phosphate Adjuvants Prepared by Precipitation at Constant pH. Part II: Physicochemical Properties. Vaccine 2000, 19 (2–3), 282–287.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Hansen B.,
    2. Malyala P.,
    3. Singh M.,
    4. Sun Y.,
    5. Srivastava I.,
    6. Hogenesch H.,
    7. Hem S. L.

    Effect of the Strength of Adsorption of HIV 1 SF162dV2gp140 to Aluminum-Containing Adjuvants on the Immune Response. J. Pharm. Sci. 2011, 100 (8), 3245–3250.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Hem S. L.,
    2. Hogenesch H.

    Relationship between Physical and Chemical Properties of Aluminum-Containing Adjuvants and Immunopotentiation. Expert Review of Vaccines 2007, 6 (5), 685–698.

    OpenUrlCrossRefPubMedWeb of Science
28. 28.↵
    1. Hem S. L.,
    2. HogenEsch H.,
    3. Middaugh C. R.,
    4. Volkin D. B.

    Preformulation Studies—The Next Advance in Aluminum Adjuvant–containing Vaccines. Vaccine 2010, 28 (31), 4868–4670.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. al-Shakhshir R. H.,
    2. Regnier F. E.,
    3. White J. L.,
    4. Hem S. L.

    Contribution of Electrostatic and Hydrophobic Interactions to the Adsorption of Proteins by Aluminium-Containing Adjuvants. Vaccine 1995, 13 (1), 41–44.

    OpenUrlCrossRefPubMed
30. 30.↵
    1. Singh M.

    1. Hem S. L. H. H.

    Aluminum-Containing Adjuvants: Properties, Formulation, and Use. In Vaccine Aadjuvants and Delivery Systems, Singh M., Ed.; J. Wiley and Sons: New York, 2007; pp 81–114.
31. 31.↵
    1. Peek L. J.,
    2. Martin T. T.,
    3. Elk Nation C.,
    4. Pegram S. A.,
    5. Middaugh C. R.

    Effects of Stabilizers on the Destabilization of Proteins upon Adsorption to Aluminum Salt Adjuvants. J. Pharm. Sci. 2007, 96 (3), 547–557.

    OpenUrlCrossRefPubMed
32. 32.↵
    1. Regnier M.,
    2. Metz B.,
    3. Tilstra W.,
    4. Hendriksen C.,
    5. Jiskoot W.,
    6. Norde W.,
    7. Kersten G.

    Structural Perturbation of Diphtheria Toxoid upon Adsorption to Aluminium Hydroxide Adjuvant. Vaccine 2012, 30 (48), 6783–6788.

    OpenUrl
33. 33.↵
    1. Jiang D.,
    2. Morefield G. L.,
    3. HogenEsch H.,
    4. Hem S. L.

    Relationship of Adsorption Mechanism of Antigens by Aluminum-Containing Adjuvants to In Vitro Elution in Interstitial Fluid. Vaccine 2006, 24 (10), 1665–1669.

    OpenUrlCrossRefPubMed
34. 34.↵
    1. Iyer S.,
    2. HogenEsch H.,
    3. Hem S. L.

    Relationship between the Degree of Antigen Adsorption to Aluminum Hydroxide Adjuvant in Interstitial Fluid and Antibody Production. Vaccine 2003, 21 (11–12), 1219–1223.

    OpenUrlCrossRefPubMed
35. 35.↵
    1. Jully V.,
    2. Mathot F.,
    3. Moniotte N.,
    4. Preat V.,
    5. Lemoine D.

    Mechanisms of Antigen Adsorption onto an Aluminum-Hydroxide Adjuvant Evaluated by High-Throughput Screening. J. Pharm. Sci. 2016, 105 (6), 1829–1836.

    OpenUrl